Anne Dejean is Research Director at INSERM, Professor at the Institut Pasteur and Head of the Laboratory of Nuclear Organization and Oncogenesis/INSERM U993. She graduated from Pierre et Marie Curie University in Paris and earned her PhD in Pierre Tiollais’ lab at the Institut Pasteur in 1983. Member of EMBO and of the French Academy of Sciences, she has received the Gagna and Van Heck Prize in 2003, the L’Oréal-UNESCO for Women in Science Awards in 2010, the Grand Prix INSERM in 2014 and the Sjöberg Prize in 2018.
A molecular biologist, Anne Dejean investigates the molecular and cellular mechanisms involved in the development of human cancers. She discovered that HBV may act as an insertional mutagen in liver cancer. Since then, Dejean’s team has contributed several pioneering concepts in the areas of nuclear receptors and tumorigenesis with their discovery that retinoic acid receptors (RAR) genes are mutated in human cancers. She first found such a mutation in HBV-associated liver cancer and cloned the RARb gene. Dejean’s team then discovered the PML-RARa oncogenic fusion protein as the causative genetic event in acute promyelocytic leukemia (APL) and dissected its molecular components, thus providing the rationale for APL treatment by retinoic acid and arsenic, the first described and so far most efficient example of oncogene-targeted therapy. They then demonstrated that a particular sub-nuclear structure, which they named the PML Nuclear Body, is disrupted in a retinoic acid-reversible manner in APL thus providing a cellular basis for APL and its treatment.
In the last twenty years, A. Dejean’s lab contributed to the emergence of the SUMO field by deciphering important biological and patho-physiological activities of this process in regulating nuclear events. Notably, A. Dejean and colleagues demonstrated that arsenic induces polysumoylation of PML-RARa leading to its degradation in APL, they generated the first mouse models for the graded ablation of sumoylation and unveiled a previously unappreciated role for SUMO that, in marking chromatin by a unique modifier, coordinates concerted regulation of cell-specific transcriptional programs. Recent projects in her lab aim at understanding how SUMO on chromatin regulates transcriptional programs and cell fate in normal and cancer states.